Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$350K Buy
1,392
+3
+0.2% +$645 0.19% 93
2026
Q1
$302K Buy
1,389
+141
+11% +$31.3K 0.19% 99
2025
Q4
$285K Sell
1,248
-133
-10% -$30.3K 0.18% 95
2025
Q3
$320K Sell
1,381
-144
-9% -$29.3K 0.22% 84
2025
Q2
$283K Buy
+1,525
New +$283K 0.22% 84
2025
Q1
– Sell
-2,175
Closed -$387K – 52
2024
Q4
$387K Sell
2,175
-462
-18% -$84.9K 0.3% 80
2024
Q3
$521K Buy
2,637
+71
+3% +$13.3K 0.45% 59
2024
Q2
$440K Sell
2,566
-14
-0.5% -$2.32K 0.44% 60
2024
Q1
$470K Buy
2,580
+103
+4% +$17.8K 0.51% 52
2023
Q4
$384K Buy
+2,477
New +$361K 0.48% 52

Other funds holding ABBV

FWG Investments's ABBV Position: Q2 2026 in Review

FWG Investments increased its AbbVie (ABBV) stake by 0.22% in Q2 2026, buying an estimated $645 and bringing the position to 1,392 shares worth $350K. The position accounts for 0.19% of the portfolio, ranked #93.

FWG Investments first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $521K in Q3 2024. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • FWG Investments held 1,392 shares of AbbVie worth $350K as of Q2 2026.
  • FWG Investments bought 3 AbbVie shares in Q2 2026, an estimated $645.
  • AbbVie made up 0.19% of FWG Investments's portfolio in Q2 2026, its #93 holding.
  • FWG Investments first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
  • FWG Investments's AbbVie position peaked at $521K in Q3 2024.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on FWG Investments's 13F filing for Q2 2026, filed 28 Jul 2026.